Pronucleotides represent a promising alternative to improve the biological activity of nucleoside analogs against different viral diseases. Moreover, pronucleotides are valuable tools for studies concerning the nucleoside/nucleotide metabolism. The basic idea is to achieve nucleotide delivery into cells, bypassing limitations with intracellular formation of nucleotides from their nucleoside precursors. The cycloSal-concept is one of several pronucleotide systems reported so far but is the only approach in which a pronucleotide is cleaved successfully by a simple but selective chemical hydrolysis. Beside others, for the nucleoside analog d4T the application of the cycloSal-approach improved antiviral potency. In the first part, the basic concept, the chemistry, different structural modifications and their effects on the antiviral potency of the cycloSal-d4TMP triesters have been discussed in this review. In the second part, first results of a conceptional extension of the original cycloSalapproach will be summarized. Once the pronucleotides have passed the membrane, the aim is to trap the cycloSalphosphate triesters inside the cells. Therefore, enzymecleavable groups have been attached via a linker to the cycloSal-moiety.
ABSTRACT
Pronucleotides represent a promising alternative to improve the biological activity of nucleoside analogs against different viral diseases. Moreover, pronucleotides are valuable tools for studies concerning the nucleoside/nucleotide metabolism. The basic idea is to achieve nucleotide delivery into cells, bypassing limitations with intracellular formation of nucleotides from their nucleoside precursors. The cycloSal-concept is one of several pronucleotide systems reported so far but is the only approach in which a pronucleotide is cleaved successfully by a simple but selective chemical hydrolysis. Beside others, for the nucleoside analog d4T the application of the cycloSal-approach improved antiviral potency. In the first part, the basic concept, the chemistry, different structural modifications and their effects on the antiviral potency of the cycloSal-d4TMP triesters have been discussed in this review. In the second part, first results of a conceptional extension of the original cycloSalapproach will be summarized. Once the pronucleotides have passed the membrane, the aim is to trap the cycloSalphosphate triesters inside the cells. Therefore, enzymecleavable groups have been attached via a linker to the cycloSal-moiety.
INTRODUCTION
Since the discovery of 3'-azido-3'-deoxythymidine (AZT) as the first nucleoside drug for the treatment of AIDS (1), considerable efforts have been made to develop new nucleoside analogs that would be more active and less toxic inhibitors of HIV reverse transcriptase (RT) (2) . These analogs differ from the natural nucleosides with regard to modifications of the glycon and/or the aglycon residue (3) . Today, synthetic nucleoside mimetics represent a highly valuable source of antiviral compounds that contribute significantly to the arsenal of agents for the treatment of viral diseases, e.g. HIV, herpes and hepatitis virus infections. The general mode of action of nucleoside analogs is through the inhibition of DNA polymerases, including reverse transcriptase, by acting as competitive inhibitors and/or as DNA chain terminators. To act as DNA chain termination agents/polymerase inhibitors, intracellular conversion of the nucleoside analogs into their 5'-mono-, 5'-di-and finally 5'-triphosphates is a prerequisite after cell penetration (2, 4) . However, the efficient anabolism to the corresponding nucleoside analog triphosphates often is a major hurdle due to limited anabolic phosphorylation or catabolic processes as deamination of the aglycon or cleavage of the glycosidic bond. Therefore, their eventual therapeutic efficacy is compromised (2, 5) . For example, the first phosphorylation step of the anti-HIV active dideoxynucleoside analog 2',3'-dideoxy-2',3'-didehydrothymidine (d4T) 1 (6) (7) (8) (Figure 1 ) into d4T 5'-monophosphate (d4TMP) catalyzed by thymidine kinase (TK) is the critical rate-limiting step in human cells (9) .
Despite the example given above, the intracellular fate of the majority of nucleoside analogs has not been studied in detail. These compounds are often exclusively tested as nucleosides and discarded if found inactive. As they are rarely studied against the target polymerases as triphosphates and thus ends in a black-box metabolism ( Figure 2 ).
However, a lack of uncovering where the metabolic blockade exists prevents further successful development. On the other hand, knowing the limitations upon phosphorylation of a nucleoside may offer a chance to develop derivatives with improved biological potential. In principle, the direct administration of nucleotides like d4TMP should bypass the limiting step in the thymidine kinase-based anabolism of some nucleosides and thus improve their biological activity. Unfortunately, nucleotides are very polar molecules and do not easily pass cellular membranes. However, this difficulty can be surmounted by linking suitably degradable lipophilic carrier groups to the phosphate moiety that lead to neutral, membrane-permeable nucleotide delivery systems (pronucleotide approach; Figure 1 ) (10) (11) (12) (13) (14) .
Two masking groups are necessary in order to obtain a neutral, lipophilic phosphate ester due to the presence of at least one negatively charged phosphate oxygen under physiological conditions. The pK A 1 of a phosphate monoester is ∼1.6 and pK A 2 is ∼6.6, which means there is an equilibrium between the mono-and the dianion in neutral solution. Moreover, the efficient intracellular delivery of nucleotides from a pronucleotide requires the design of a specific delivery mechanism. Several strategies using different nucleotide delivery mechanisms have been developed to achieve this goal (10) (11) (12) (13) (14) . Among these, simple systems like dialkyl-, diphenyland dibenzyl phosphate triesters based on pure chemical hydrolysis proved to be unsuccessful because after the first hydrolysis of the neutral phosphate triester, the resulting phosphate diester is often far too stable to undergo further chemical hydrolysis (10, 11, 13, 14) . More recent pronucleotide approaches are based on the principle of selective enzymatic or chemical activation of the masking group, which leads to a second, spontaneous reaction (tripartate prodrug system (15) (11) (12) (13) . All these enzyme-triggered approaches have demonstrated that the successful intracellular delivery of nucleotides is indeed possible. However, the only successful, pH-driven nucleotide delivery strategy by chemical means is the cycloSal-approach (16) . This approach, which also belongs to the group of tripartate prodrug delivery systems, has been developed in our laboratories and will be the topic of this review. The effect of differently modified cycloSal-triesters 2 and 3 of the nucleoside analog d4T will be described. Three groups of derivatives will be discussed. The so-called prototypes (2) bearing no additional substituent at the benzyl carbon atom. A second series of compounds (3) bearing alkyl residues in the benzyl position (7-position) and finally a series of triesters but having an ester-functionalized group as the X substituent but are unsubstituted in the 7-position (4) (Figure 3 ).
The first two compound series will be discussed concerning their hydrolytic behavior. These first generation compounds will offer valuable mechanistic insights into the designed cascade cleavage mechanism as well as their antiviral potential. The third series will be discussed in the last chapters of this review. These compounds may act as second generation cycloSal-pronucleotides. 
THE CYCLOSALIGENYL-PRONUCLEOTIDE APPROACH: THE FIRST GENERATION

CycloSaligenyl-nucleotides (cycloSal-NMPs) -The Design of a Concept
In contrast to the approaches mentioned previously, our aim was the development of a selective delivery mechanism that is based on an exclusively pHdependent, chemically-induced cascade mechanism (16, 17) . However, the chemically driven release of the free nucleotide from a lipophilic precursor is not as easy as it seems (18) (19) (20) (21) . By contrast to the enzymatically triggered pronucleotides (11), the cycloSal-strategy requires only one activation step to deliver the nucleotide and due to the bifunctional character of the cycloSal group the ratio of the masking unit per nucleotide molecule is 1:1. By contrast, other pronucleotide concepts employ ratios up to 4:1 (22) (23) (24) (25) . As summarized in Figure 4 , simple bis(phenyl)-5 or bis(benzyl) nucleotide triesters 6 are unable to deliver the nucleotide (26) (27) (28) . Hydrolysis always stops at the phosphate diesters 7 and 8, respectively, without formation of d4TMP 9.
Interestingly, the influence of substituents in the aromatic rings of 5 or 6 are just the opposite: while acceptors in bis(phenyl) esters 5 cause a fast hydrolysis, donors in bis(benzyl) esters 6 cause a fast cleavage to yield the diester and finally benzyl alcohol ( Figure 4 ). However, a combination of both may form the basis of a suitable pronucleotide approach. Thus, the basis of the cycloSal concept consists of a combination of two ester bond types as part of a cyclic bifunctional group (masking unit). Salicyl alcohols have been attached via a phenyl-and a benzyl ester bond. Additionally, the nucleoside analog is attached through an alkyl ester bond. Only the introduction of these three ester bonds would allow sufficient discrimination between the different phosphate ester bonds. The designed chemically-induced coupled process (tandem or cascade mechanism) is the following (17,29,30): The phenyl ester bond in the cycloSal-triester structure should be the most labile one after nucleophilic attack of hydroxide to phosphorus (S N P-reaction). The developing negative charge can be delocalized by the aromatic system which makes the phenolate the best leaving group in the triester. Cleavage yields a 2-hydroxybenzylphosphate diester 10 ( Figure 5, step a) . As a consequence of the initial step, the ortho-substituent to the benzyl ester is changed from a very weak electron-donating group (phosphate ester) to a strong electron-donating group (hydroxyl). This effect of the 2-substituent intrinsically activates the remaining masking group and this induces a spontaneous rupture of diester 10 to yield the nucleotide and salicyl alcohols 11 (R = H) and 12 (R = alkyl) (cascade reaction; step b 1 and b 2 ). This rupture proceeds presumably after intramolecular proton transfer (intermediate 13) via zwitterion 14 or 2-quinone methide 15. By this pathway, a cleavage mechanism is achieved that takes place within the masking group only, and so prevents a pseudorotation process (18) that may partly lead to nucleoside liberation instead of the nucleotide. This is the preferred pathway via the benzyl phosphate diester intermediate 10.
Although unfavored, a cleavage of the benzyl ester bond should also be taken into account (step c). From literature it is known that benzyl esters are cleaved via S N 1-type C benzyl -O bond rupture which leads to the formation of a stabilized benzyl cation and an anionic phosphate ester group (intermediate 16). The cation 16 is rapidly trapped by water to yield the phenyl phosphate diester of type 17 ( Figure 5 ). However, no further hydrolysis can be expected from this diester, thus hindering nucleotide release. The reason is the formation of a negative charge at the phosphorus atom. This prevents a second nucleophilic attack at the phosphorus atom in phenyl phosphate diesters. It also would decrease the leaving group properties of the 5'-nucleoside phosphate fragment in benzyl phosphate diesters (19) (20) (21) . Consequently, this C benzyl -O bond rupture would lead to a dead end ( Figure 5 ) by formation of the phenyl phosphate diester 17.
Salicyl alcohols 11,12 used as masking units were tested for their biological potency but showed neither antiviral activity nor cytotoxicity (29, 30) . Further in-vivo studies in mice did not show toxic side effects (feeding of mice with 250 mg/kg of 3-methyl-salicyl alcohol does not cause any visible toxic effects (unpublished results). It should be added that salicyl alcohol (saligenin) is used as part of the antirheumatic and analgetic drug Salicin (2-(hydroxymethyl)phenyl-β-D-glucopyranoside; Assalix  ) (31) . β-Glucosidases hydrolyze Salicin to D-glucose and saligenin and the latter is then slowly oxidized by cytochrome P450 to salicylic acid in the blood and in the liver.
Chemistry
For the synthesis of the prototype cycloSald4TMP triesters the salicyl alcohols 11 had to be prepared first from the corresponding salicylic aldehydes, -acids or -esters (32) by standard reduction protocols (NaBH 4 or LiAlH 4 (33); Figure 6 ) in high yields. In most cases, the aldehydes/acids/esters were not commercially available. Diols 11 (for triesters 2) then have been synthesized starting with appropriately substituted phenols. Selective ortho-formylations have been achieved according to or the Rieche-formylation protocols (35) . Both methods led to salicyl aldehydes, which then could be reduced to the corresponding diols 11. Alternatives are the direct hydroxymethylation according to Nagata (36) or a direct hydroxymethylation using formaldehyde in aqueous basic medium (37) . The latter methods are the mildest of the procedures above ( Figure 6 ).
These generally highly efficient methods are suitable for the synthesis of the prototype cycloSalderivatives without substituent in the benzyl position. For the second series of derivatives, 7-methylated diols 12 (for triesters 3) were prepared by alkylation of salicyl aldehyde with methyllithium (38) or dichloromethyllithium (39) to give diols 12a and 12c. 7-Chloromethylsalicyl alcohol 12d was prepared by chlorination of ortho-hydroxy acetophenone using 2,3,4,5,6,6-hexachloro-2,4-cyclohexadiene-1-one (40) to give the ketone intermediate which was reduced to give the alcohol. The 7-trichloromethyl derivative 12b was synthesized by the Nagata protocol using chloral instead of formaldehyde, while double 6,7-modified salicyl alcohol 12e was prepared by nucleophilic substitution of the fluorine in 2-chloro-6-fluoro-benzaldehyde by hydroxide (41) and subsequent aldol-type addition as mentioned above.
The synthesis of the cycloSal-pronucleotides has been carried out using reactive phosphorus(III)-reagents ( Figure 7 ). Therefore, diols 11,12 were reacted with phosphorus trichloride to give the cyclic chlorophosphites 18. Phosphites 18 were reacted directly with the nucleoside analog, e.g. d4T, in the presence of diisopropylethylamine (DIPEA; Hünig`s base) to yield the cyclic phosphite triesters which were oxidized in a one-pot-reaction using tbutylhydroperoxide (TBHP) or dimethyldioxirane. The phosphate triesters 2-4 were obtained in reasonable yields (50-73%) as mixtures of stereoisomers (29, 30) .
Alternatively, chlorophosphites 18 were treated with diisopropylamine to yield the phosphoramidites 19. The coupling with the nucleoside analog was carried out in acetonitrile in the presence of pyridinium chloride or imidazolium triflate as coupling activator. In some cases the latter procedure resulted in yields of > 90% using imidazolium triflate as activator (42).
Proof-of-Principle 3.3.1. D4TMP-Release from cycloSal-d4TMP Pronucleotides
Extensive studies have been performed in order to investigate the designed delivery mechanism of d4TMP from the cycloSal-triesters (30, 43) . Chemical hydrolysis studies in different buffer solutions at different pH values proved that all prototype compounds released selectively d4TMP in a pH dependent manner. As second product, the salicyl alcohols 11 have been detected also by means of HPLC analysis. D4TMP has been identified undoubtedly by using ion-pairing eluents and the coelution technique. The half-lives of the triesters have been determined from these studies and are summarized in (Table 1) . Within the prototype compound series, the following interesting effects were observed: As expected, the half-lives depend on the substitution pattern of the aromatic ring (11, 16, 30) . In general, acceptor substituents like the 5-or 6-chloro atom cause a decrease in hydrolytic stability while donorsubstituents like 3-methyl-, 3,5-dimethyl-and particular 3-t-butyl or 3,5-di-t-butyl group(s) lead to an increased stability with respect to the unsubstituted prototype triester 2c.
However, the phenyl ring substituent in the 3-(2e) and 5-position (2d), respectively, showed a stabilizing effect for the first (t 1/2 = 5.1 h) and a destabilizing effect for the latter (t 1/2 = 3.1 h) compared to a t 1/2 of 4.4 hours for the unsubstituted prototype triester 2c. It should be mentioned that these differences are out of the experimental error (±0.2 h) and are relevant. Our interpretation is that the phenyl ring in the case of 5-phenyl-cycloSal-d4TMP 2d is involved in the delocalization of the negative charge appearing after the initial cleavage of the phenyl ester bond to give the benzyl phosphate diester 10 ( Figure 5 ). Thus, the accelerating effect dominates due to a (-)M-effect of the phenyl group and the stability of the triesters decreases. In contrast, the rotation of the phenyl-aryl bond in 3-phenyl-cycloSal-d4TMP 2e is hindered due to the bulky dioxaphosphorine-2-oxide ring and the delocalization of the negative charge in diester 10 is less effective. Thus a weak donor (+)I-effect dominates and the stability increases. However, this donating effect is considerably weaker as compared to the strong (+)I-effect of a methyl group, as reflected by the longer half-life of 3-methyl-cycloSald4TMP 2f. Another contribution of the 3-phenyl ring may be hindering the nucleophilic attack of water or hydroxide to the P-atom due to its lipophilicity by making the trajectory less available. By contrast, the presence of t-butyl groups has an unexpectedly big influence to the hydrolysis stability. Although the electron-donating property of a tbutyl group differs only slightly from the +I-effect of a methyl group, triesters 2h (3-tBu) and 2i (3,5-tBu) showed considerably higher half-lives as compared to the methyl counterparts 2f and 2g. We attribute this to differences in the lipophilicity and therefore in the accessibility of the phosphate group.
It is interesting to note that the compounds bearing an extended aromatic system 2k-m (43) all showed a decreased hydrolytic stability as compared to the unsubstituted prototype triester 2c. Half-lives ranged between 2.8 h and 1.4 h for compound benzo[a]-(2k), benzo[b]-(2l) and benzo[c]-cycloSal-d4TMP 2m. This may be explained by the increasing stabilization of the negative charge in the extended aromatic ring system particularly in the case of the benzo[b]-derivative 2l as compared to the monocyclic prototype counterparts.
In addition to these HPLC-based studies we were able to study the delivery mechanism by a 31 P-NMRexperiment. The reason for using this technique was that the detection limit judged by integration of the resonance signals of possible reaction side products in the NMR technique using the 31 P-nucleus as a probe is much lower (1%) as compared with the HPLC method (∼5%). However, phosphate buffer is not an appropriate buffer system for this experiment. Compounds were dissolved therefore in an imidazole/HCl buffer adjusted to pH 7.3. A similar NMR experiment using only a DMSO/water mixture has been done earlier in our lab for the hydrolysis of 5-nitro-cycloSal-d4TMP (30) . In that case d4TMP has been detected as the only hydrolysis product pointing to an entirely selective delivery reaction. The prototype cycloSal-d4TMP 2c led to 99% formation of d4TMP in the imidazole/HCl buffer, pH 7.3. Moreover, 1% of phenyl phosphate diester of type 17 ( Figure 5 ) was detected (Table 1) . Diester 17 was entirely stable for several weeks in the NMR tube at 37°C. This diester of the S N 1-type reaction has also been found in other cases in amounts of 3% (3-phenyl derivative 2e) until up to 8% for the 3,5-dimethyl triester 2g and 3-t-butyl triester 2h (Table 1 ). The formation of the phenyl phosphate diesters could not been followed in the HPLC studies due to the lower detection sensitivity. The benzoannulated benzo[a]-and benzo[c]-cycloSal-triesters 2k, 2m formed 9% and 12% of the phenyl phosphate diester under the same reaction conditions, respectively. The difference between the above benzo-annulated triesters 2k, 2m and benzo[b]-cycloSal-d4TMP 2l (3% diester 17) results from a better mesomeric stabilization of the cation intermediate of the first two compounds. This additional stabilization increases the rate of the S N 1-type bond rupture. By contrast, the worst case was found for the introduction of two t-butyl groups in the 3 and 5 position (compound 2i) led to the formation of 34% of the phenyl phosphate diester. Here, the concurrent S N 1-type reaction plays a considerable role in the degradation of triester 2i.
In contrast, 5-chloro-(2a), 6-chloro-(2b) and 5-phenylcycloSal-d4TMPs 2d turned out to deliver d4TMP exclusively. No side products were observed in the NMR experiment.
In conclusion, the S N P-type hydrolysis of the prototype cycloSal-triesters showed a strongly favored delivery of d4TMP following the designed cascade mechanism. However, a small amount of the phenyl phosphate diester 17 was also formed via an S N 1-type reaction. Hydrolysis half-lives may be controlled by introduction of appropriate substituents in the aryl moiety. Benzo-annulated compounds do not show favorable properties with respect to the half-life as well as delivery mechanism. It should be added that an additional hydrolysis study has been done in 18 O-labeled water. This experiment clearly proved the spontaneous second step involving a zwitter-ion or a quinone methide (16, 30) .
Very interesting effects have been observed for the second series of compounds. First, 7-methyl-cycloSald4TMP 3a has been investigated. Surprisingly, an enormous decrease in chemical stability was measured. The half-life dropped to 0.25 h (compared to 4.4 h for prototype triester 2c) and even product distribution has changed dramatically. NMR studies confirmed that the major product was the phenyl phosphate diester 17 (83%; Table  1 ). Obviously, in this case the S N 1-type reaction is preferred. This may be due to the formation of a secondary benzyl cation intermediate as compared to a primary benzyl cation in the prototype cases. The additional alkyl residue stabilizes the cation by a (+)I-effect. This interpretation has been further confirmed by density functional theory (DFT)-calculations on the B3LYP/6-311G(d,p) level on model compounds of the prodrug systems (44) . The activation energy barrier for the initial S N 1 reaction is considerably lower for 7-methyl-cycloSal-methylMP compared to the prototype triester analog (unpublished results). On the other Figure 8 . Hydrolysis of the 7-alkyl-modified cycloSal-d4TMP triesters 3.
hand, this predominant S N 1-type reaction should be avoided by reduction of the methyl (+)I-effect or by introduction of a strong electron-withdrawing substituent like a chloro-atom in the 6-position of the aromatic ring. Both should decrease the stability of the intermediate benzyl cation and therefore should favor again the phenyl ester bond cleavage. Hence, the corresponding cycloSaltriesters 3b-3e bearing a 7-trichloromethyl, a 7-dichloromethyl and a 7-chloromethyl and a 6-chloro,7-methyl group instead of a 7-methyl group (3a) were prepared. The half-lives of these compounds are listed in (Table 1) . NMR studies proved in all cases that the favored degradation pathway is again the phenyl ester bond cleavage giving the benzyl phosphate diesters 10a-d (Figure 8) . Unexpectedly, the intermediate benzyl diester bearing a 7-trichloromethyl group proved to be entirely stable in phosphate buffer, pH 7.3 as well as in imidazole/HCl, pH 7.3. No d4TMP formation was observed. By introduction of three chloro atoms, the second, spontaneous step leading to the formation of d4TMP is prevented completely (Figure 8 ). By introducing only two chloro atoms, 7-dichloromethyl-cycloSal-d4TMP 3c gave the diester 10 in 93% which subsequently delivers d4TMP. However, the reaction proceeds very slowly. 7-chloromethyl-cycloSal-d4TMP 3d led to an entirely selective cleavage of the triester to give the benzyl phosphate diester 10 that then delivered d4TMP as known for the prototype triesters 2. Thus, a single chloro atom in the 7-methyl group completely turns the delivery mechanism from a predominant S N 1-type reaction into the desired highly selective S N P-reaction (Figure 8 )! For 6-chloro-7-methyl-cycloSal-d4TMP 3e similar results were obtained: Again a highly selective d4TMP delivery was observed. Obviously, the introduction of the destabilizing 6-chloro atom overcompensates the stabilizing effect of the 7-methyl group efficiently. It should be mentioned that also the prototype 6-chlorocycloSal-d4TMP 2b gave an exclusive d4TMP delivery as discussed above. The additional 7-methyl group did not interfere although it results in an increase in chemical stability (0.9 h (2b) vs. 2.2 h (3e)). Finally, the tremendous effect of a halogen atom in the 6-position leading only to the formation of d4TMP 9 has been transferred to the worst-case 3,5-t-butyl cycloSal-triester 2i. Our aim was to avoid or at least to minimize the formation of the hydrolytically stabile phenyl phosphate diester. The introduction of a fluorine atom in the 6-position in addition to two t-butyl groups in the 3-and 5-position in triester 2j, the concurrent S N 1-type reaction should be limited and, moreover, this fluorine atom should have an impact on the chemical stability at the same time (45) . Triester 2j showed as expected a pronounced decrease in chemical stability (half-life 6.2 h instead of 73 h for 2i) and moreover, to our surprise, this compound delivers d4TMP 9 highly selectively (0% for 2j instead of 34% for 2i)! Thus, again the concurrent S N 1-type cleavage of the triesters was entirely excluded.
In conclusion, it became apparent that besides the d4TMP formation the prototype triesters lead to a small amount of the phenyl phosphate diesters 17, too. However, this can be efficiently avoided by introduction of an electron-withdrawing 6-substituent or by a mono-acceptorsubstituted methyl group in the 7-benzyl position.
No evidence of an enzymatic degradation in RPMI-1640 medium containing 10% fetal calf serum (pH 7.3) has been observed (data not shown). Studies in CEMcell extracts showed that the hydrolysis half-lives slightly decreased only as compared to the buffer hydrolyses (unpublished results). Further studies of the prototype triesters in human serum (10% serum in phosphate buffer) exhibited no difference in stability as compared to the buffer hydrolysis studies. Again no enzymatic contribution could be detected and thus confirmed the initial idea of a delivery mechanism independent to enzymatic activation. All data obtained from hydrolysis and NMR studies are in perfect agreement with the designed degradation cascade-reaction mechanism and showed convincingly that the mechanism may be controlled efficiently by structural modification of the cycloSal-moiety ( Figure 5 ).
Antiviral Activity
The antiviral potency of the cycloSal-nucleotides against HIV-1 and -2 in CEM cells was assessed (16, 30) . It became apparent that the unsubstituted prototype 2c, 3-phenyl-(2e), 3-methyl-(2f) as well as 3,5-dimethylcycloSal-d4TMP 2g showed comparable or even higher antiviral potency (0.087 µM) in a wild-type T-lymphocytic cell line (CEM/O) compared to d4T 1 (0.18 µM, Table 1 ). Moreover, particularly striking is the complete retention of the antiviral potency in mutant thymidine kinase-deficient cells (CEM/TK -) of the unsubstituted (2c), 3-phenyl-(2e), 3-methyl-(2f), 3,5-dimethyl-(2g), 3-t-butyl-(2h), and 3,5-t-butyl-6-fluoro-(2j) substituted triesters. The antiviral data and the hydrolysis half-lives clearly point to the fact that certain stability is needed, but beyond this point no further improvement of activity could be observed.
By contrast, the short half-life of the 5-chlorotriester 2a (t 1/2 = 1.1 h) seems to be responsible for a considerable loss of antiviral activity in the CEM/TK -cell assay although the antiviral activity in the TK -competent cells (CEM/O cells) was comparable to that of d4T. The compound hydrolyzes extracellularly to yield d4TMP that can not be taken up by the cells. After extracellular dephosphorylation, d4T is taken up inside the cells and can be converted into the triphosphate. This is only possible in the TK -competent cells. Similar results were obtained for the 6-chloro derivative and all the triesters bearing the extended aromatic ring system. All of them are losing activity in the CEM/TK -cell assay. An interesting observation has been made in the case of the unsubstituted, the 5-phenyl-, and the 3-phenyl prototype triesters 2c, 2d, 2e, respectively. While the 3-phenyl and the unsubstituted triester retained all antiviral potency in the CEM/TK -cells, 5-phenyl-cycloSal-d4TMP 2d loses activity (4-fold). Halflives were found to be 5.1 h, 4.4 h and 3.1 h. This may point to a threshold of about 4 h of hydrolytic stability needed in order to get a biologically active compound in the CEM/TK -cell assay. Having this in mind it is also reasonable that all compounds of the second series bearing the additional group in the 7-position and 3,5-t-butylcycloSal-triester 2i lack antiviral activity in the CEM/ TK -cells. Even the most stable derivative 7-chloromethylcycloSal-d4TMP 3d lost all antiviral potency in the TK -deficient cell line (Table 1) . Moreover, also a loss in activity has been found for some of the compounds in the CEM/O cells. This can be attributed to the fact that predominantly the phenyl phosphate diester 17 was formed or a stable benzyl phosphate diester 10 was formed that did not release d4TMP efficiently in the time scale of the invitro assay. It should be added that from experiments using an isolated recombinant RT/RNA/DNA template primer it became clear that the cycloSal-triesters themselves have no inhibitory effect on DNA-synthesis, which is consistent with a mechanism of action for the cycloSal-triesters that relies on the formation of free d4TTP. Taken together, these results confirm i) the cellular uptake of the compounds, ii) the highly selective intracellular delivery of d4TMP and iii) the independence of the biological activity on cellular thymidine kinase activation for some of the described cycloSal-phosphate triesters.
Nevertheless, the in vitro anti-HIV assays give only an indirect proof of the intracellular delivery of d4TMP. Therefore, a series of incubation experiments with wild-type CEM/O and CEM/TK -cells and radiolabeled 3-methyl-cycloSal-d4TMP 2f (tritium-label in the methyl group of thymine) was conducted (46) . The amount of d4TMP in CEM/O cells was considerably higher (15-fold, 6 h incubations) as compared to the amount of d4TMP resulting from the metabolism of d4T in the same cell line. In addition, an increase in the concentration of d4TTP was observed (16-fold, 6 h incubation), which may explain the higher activity of the prototype cycloSal-d4TMPs in wildtype CEM cells compared to d4T. These results are consistent with a mechanism of the cycloSal-d4TMPs that successfully bypasses thymidine kinase and releases d4TMP inside the cells.
Furthermore, the cycloSal-d4TMP triesters demonstrated significant antiviral activity in AZT-resistant H9 r AZT 250 cells (47) . The resistance is concomitant with a five-fold lower expression of the TK gene in comparison to parental H9 cells. The consequence is that also d4T showed reduced antiviral potency due to insufficient phosphorylation. In contrast, the prototype cycloSald4TMP 2c proved to be equipotent in parental and in H9 Finally, it should be mentioned that, beside to d4T 1, the cycloSal-approach also has been applied to the following nucleoside analogs: 2',3'-dideoxyadenosine 20 and 2',3'-dideoxy-2',3'-didehydroadenosine 21 (48), 2'-ara-fluoro-2',3'-dideoxyadenosine 22 and 2'-ribo-fluoro-2',3'-dideoxyadenosine 23 (49), 3'-azidothymidine (AZT) 24 (50), 5-fluoro-2'-deoxyuridine (5F-dU) 25 (51), carbovir 26 and abacavir 27 (52), acyclovir (ACV) 28 (53, 54) and most recently very successful to 5-(E)-bromovinyl-2'-deoxyuridine (BVdU) 29 (55, 56) (Figure 9 ). Chemical hydrolysis studies showed in all cases the delivery of the corresponding nucleotides. In most of the cases the antiviral evaluation revealed the improvement of the antiviral potency except the cycloSal-AZTMP and cycloSal-FdUMP derivatives. The reason for the failure in those cases is a intracellular dephosphorylation of the released nucleotides to give the nucleosides. The involved enzyme seems to be 3',5'-(deoxy)nucleotidase (57).
APPLICATION OF THE CYCLOSAL-APPROACH TO THE ANTI-HERPES DRUG BVDU
As mentioned above, the cycloSal-concept has been applied to the nucleoside analogue 5-[(E)-2-bromovinyl]-2'-deoxyuridine (BVdU or Brivudin 29, Figure 9 ) which is a very potent and highly selective inhibitor of the replication of HSV-1 and particularly VZV (58) . By contrast, BVdU is not markedly active against HSV-2 and EBV. Again, selectivity as inhibitor primarily depends upon a specific activation by HSV-encoded thymidine-kinase (TK) to the mono-and diphosphate and finally to the triphosphate by cellular enzymes (59) . BVdUtriphosphate (BVdUTP) can act either as an inhibitor of the cellular DNA polymerase or alternate substrate that would render the DNA more prone to degradation when incorporated in DNA (60) . Some limitations for the use of BVdU are known: lack of activity during virus latency because of missing viral TK; drug resistant virus strains are known and BVdU will be enzymatically degraded to the nucleobase 5-[(E)-2-bromovinyl]uracil within 2-3 h from the bloodstream (60) . Moreover, it has been shown that EBV does not express a HSV-like thymidine kinase and this may be the reason why BVdU is inactive to inhibit EBV-replication (Table 2) . Obviously, cytosolic TK are unable to activate BVdU. The aim was to prove if the cycloSal-concept is able to broaden the application of BVdU against Epstein-Barr-virus (EBV) caused infections (61) . Such infections play a significant role as secondary infection in e.g. AIDS patients. It should be mentioned that two reports on pronucleotides of BVDU have been published before but both were unsuccessful (62, 63) . Two different series of cycloSal-BVdUMP triesters were synthesized: cycloSal-BVDUMP 30 having different substituents in the aromatic residue and a series of 3'-Oesterified 3-methyl-cycloSal-derivatives 31 and 32 (55, 56) . As 3'-O-modification different lipophilic carboxylic acids (31) as well as α-amino acids (32) have been used ( Figure  10 ).
The compounds were prepared using 3'-Olevulinylated BVdU or 3'-O-esterified BVdU derived from N-Boc-α-aminoacids like L-/D-alanine, L-phenylalanine as well as carboxylic acids. These compounds were phosphorylated using the phosphoramidite/oxidation method (42) . The levulinyl protection group was removed by treatment of the triester with hydrazine hydrate. The NBoc protecting group was removed by treatment with trifluoroacetic acid (55, 56) . First, 3-methyl-cycloSal-BVdUMP 30c as well as the 3'-O-acetyl derivative 31a were tested for inhibition of VZV replication. BVdU 29 prove to be highly active against VZV/TK + with EC 50 s of 0.033 µM and 0.010 µM using the YS and the OKA strain, respectively. As expected, this activity was completely lost when VZV/ TK -(YS/R and O7/1 strain; > 200 µM) was used. Interestingly, both 3-methyl-cycloSal-BVdUMP triesters 30c, 31a showed comparable anti-VZV activity as compared to the parent. However, both are also loosing all the antiviral activity against the VZV/ TK -strains (EC 50 > 50 µM). This led to the conclusion that only the VZV/TK associated viral thymidylate kinase activity is involved in the intracellular formation of BVdUDP. Thus, cellular enzymes are unable to phosphorylate BVdUMP.
Much more interesting were the results obtained in the assays against inhibition of EBV replication in P3HR-1 cells (56) . BVdU itself was found to be entirely inactive (EC 50 > 100 µM in the EBV DNA synthesis assay as well as the EB-VCA expression assay) (54). It has been described that EBV does not possess a HSV-1-like thymidine kinase. The lack of activity of BVdU clearly indicates that cellular kinases are unable to activate BVdU into its monophosphate BVdUMP. Strikingly, some of the cycloSal-BVdUMP triesters exhibited pronounced anti-EBV activity. The most active compound was the prototype 5-methoxy-cycloSal-BVDUMP 30b ( Table 2) . As compared to the inactive BVdU 29, triester 30b was >166-fold more active and about 4-fold more active than the reference compound acyclovir (ACV).
The 3'-alanine cycloSal-triesters showed antiviral activity that was 5-(D-32a) and 12-fold (L-32a) lower as compared to 30c but both were still significantly more potent than BVdU. It was interesting to realize that in both cases the attachment of L-amino acids led to lower antiviral activity as compared to the unnatural D-amino acids. Surprisingly, both derivatives 31 esterified with carboxylic acids devoid of any antiviral activity (Table 2) . Obviously, BVdUMP 33 released from the cycloSal-pronucleotide led to antiviral activity and thus the phosphorylation of BVdUMP into the ultimate metabolite BVdUTP seems to be achieved by cellular enzymes. Such insights of biosynthetic pathways are only possible since cycloSalpronucleotides led to an intracellular delivery of the corresponding nucleotides. Thus, this is a good example that cycloSal-triesters may also be used as biochemical tools to study nucleoside metabolism.
In order to understand the different behavior of the mentioned 3-methyl-cycloSal-BVdUMP triesters studies using isolated carboxyesterase (64) and cell extracts from CEM/O cells as well as P3HR-1 cells (that were used for the antiviral evaluation) were performed (56).
In studies concerning a possible enzymatic cleavage caused by intracellular (carboxy)esterases, the triesters 31a,b and D/L-32a, L-32b were treated with 50 units of pig liver esterase (PLE) in phosphate buffer, pH 7.3 as a model for enzymatic cleavage. The half-lives were found to be markedly lower as compared to previous studies in phosphate buffer at the same pH (Table 2 ). More importantly, the product was in all cases the 3'-O-deesterified 3-methyl-cycloSal-BVdUMP 30c which clearly proves an efficient enzymatic cleavage that also explains the shorter half-lives found in the study (given half-lives represent only the disappearance of the cycloSal-triester). After enzymatic deesterification, 3-methyl-cycloSalBVdUMP released BVdUMP as in the chemical hydrolysis studies. In these incubation studies 3'-O-esterified BVdUMP was not detected. It is worth mentioning that the 3'-O-α-amino acid containing triesters 32 were cleaved to the same extent as the 3'-O-carboxylic acid bearing derivatives 31. Hence, the reason for the significant differences in antiviral activity remains unclear (Table 2) .
A few striking differences have been observed in P3HR-1 cell extracts. Triester 30c was hydrolyzed to BVdUMP with a half-life comparable to that observed in chemical hydrolysis studies (t 1/2 = 8.9 h; Table 3 ). Thus, the degradation is chemically driven and not enzymatically. Again, no cBVdUMP 34 was detected (65) . In contrast to the chemical hydrolyses, BVdU 29 was observed also to a minor extend after 4 h (5%) and 8 h (22%) which is due to an enzymatic dephosphorylation of BVdUMP by phosphatases/nucleotidases (path f, Figure 11) . In separate studies, BVdUMP was converted to an extent of 13% to BVdU within 4 h.
The hydrolyses of the 3'-O-acyl derivatives 31 exhibited a clear difference with respect to the attached acid. For the 3'-O-Ac-derivative 31a enzymatic deesterification by carboxyesterases yielded the prototype 30c as the major product (32%) but only 9% of BVdUMP was found. By contrast, the 3'-O-Prop derivative 31b yielded the 3'-O-esterified BVdUMP derivatives 35c as the major hydrolysis products due to the chemically driven cleavage of the cycloSal-mask (path b, Figure 11 ) ( Table  3 ).
The situation was significantly different for the α-aminoacid modified 3-methyl-cycloSal-BVdUMP triesters 32a,b. All four compounds were rapidly deesterified to yield the prototype triester 30c as major product (40-44%) . This result also differs considerably to the PLE studies described above. The half-lives were dependent on the stereochemistry and the type of the α-amino acid (Table 3) . As for 3-methyl-cycloSal-BVdUMP 30c, 33 % BVdUMP has been formed starting from amino acid esters D/L-53a,b after incubation for 8 hours (Table 3) .
Comparable data were obtained in the CEM/O cell extract incubation. The major difference was that the triesters yielded higher amounts of BVdUMP after 8 h as in the P3HR-1 extracts. Again, the triesters modified at C3' with a carboxylic acid exhibited considerable lower amounts of BVdUMP (1-22%, Table 3 ). Moreover, dephosphorylation in CEM/O cell extracts BVdUMP proceeded to a lower extend compared to P3HR-1 cell extracts (13% vs. 26%, respectively).
Taking these data together, the experiments with both extracts result in a much higher formation of BVdUMP for triesters 30 and aminoacid-modified triesters 32 as compared to the carboxylic acid-modified derivatives. Extrapolated to a cellular situation, this would lead to higher BVdUMP concentrations and a higher degree of forward phosphorylation to the ultimate metabolite BVdUTP.
The promising anti-EBV data of some cycloSalBVdUMP triesters (e.g. 30b) proved that by applying the cycloSal-approach, the inactive BVdU can be converted into a anti-EBV active agent that is even more active than the reference acyclovir.
5.
SECOND GENERATION CYCLOSAL-PHOSPHATE TRIESTERS
"Lock-in"-cycloSal-d4TMP Triesters -A conceptional Extension of the trojan Horse Concept
The compounds described so far belong to the first generation compounds of the cycloSal-concept. Although these first generation cycloSal-triesters led to convincing antiviral results, the use of a chemical hydrolysis mechanism may also have some limitations. We have clearly shown for several cycloSal-triesters that an enzymatic contribution to the hydrolysis could not be found neither in cell extracts nor in human serum. Moreover, we have clearly proven that the lipophilic cycloSal-triesters are able to penetrate the cell membranes and deliver nucleotides inside the cell. However, it can not be excluded that the chemical hydrolysis also takes place outside the cells. In addition, although the compounds are lipophilic enough to migrate inside the cells we can not exclude that they also can diffuse in the opposite direction through the membrane. This would lead to the formation of an equilibrium. In order to avoid such a back-diffusion we planned to convert the triesters inside the cell into a much more polar compound by an enzymatic reaction, thus preventing the efflux ("lock-in" mechanism; Figure 12 ). Therefore, we used an (carboxy)esterase reaction on a carboxylic ester attached to the cycloSal-aromatic ring via a linker. As a linker, a C2-alkyl chain was introduced. The ethylene spacer should separate the ester group efficiently from the aromatic ring in order to avoid an electronic effect on the hydrolysis of the phosphate triester moiety. Due to results obtained from the first generation cycloSal-phosphate triesters, two positions in the cycloSalmoiety have been selected for the introduction of the esterspacer residue: the 3-and the 5-position. As an ester group, two possibilities were used: i) esterification of a cycloSalacid (36, 37) with an alcohol and ii) esterification of a cycloSal-alcohol (38,39) with a carboxylic acid leading to compound series 40,41 and 42,43, respectively ( Figure 13 ).
After enzymatic cleavage, the former triesters 40,41 should lead to the formation of a free carboxylic acid residue that should be deprotonated under physiological pH-conditions while the latter triesters 42,43 would lead to a free alcohol group. Different esters bearing linear or branched alkyl groups were introduced and the new concept first has been applied to the nucleoside analog d4T.
Chemistry
The synthesis of the cycloSal-pronucleotides has been done as for the prototype compounds 2 and 3, respectively, using the above mentioned reactive phosphorus(III)-reagents ( Figure 14) . Again, the phosphate triesters 40-43 were obtained in reasonable yields as diastereomeric mixtures.
Originally, salicyl alcohols 11 have been prepared from the corresponding salicylic aldehydes or -acids by standard reduction protocols. However, the aldehydes/acids that were used here were not commercially available. Then, diols 11 have been synthesized from the phenols 44. Selective ortho-hydroxymethylation was possible according to Nagata (36) . This method is the mildest procedure used leading to the diols 11 without any side reaction in the ester moiety. Unfortunately, there is no generally applicable method for the preparation of the substituted phenols 44 bearing the ester-spacer residue. The 3-(2-hydroxyphenyl)alkylpropionates were prepared from dihydrocoumarin 45 by transesterification with methanol or 2-propanol in the presence of H 2 SO 4 in 96% and 73% yield (step A). The methyl ester of 4-hydroxyphenylpropionate 46 was formed by refluxing the acid, methanol and sulfuric acid in CH 2 Cl 2 (step C, 93% yield). The t-butyl esters of 2-(47) and 3-(4-hydroxyphenyl)propionic acid 46 can be isolated in 80% yield using DMF-dineopentylacetale and t-butanol (step B) (66) . 3-(4-Hydroxyphenyl)propionic acid 46 was also the starting material for the i-propyl ester that has been formed in 2-propanol and with HCl-gas in 62% yield (step D) (67) . The acetyl esters 2-(hydroxyphenyl)ethanols 48,49 were prepared by transesterification from ethylacetate catalyzed by SiO 2 •NaHSO 4 in 95% and 60% yield (step E) (68). Both, 2-(2-hydroxyphenyl)ethylpivalate and 2-(4-hydroxyphenyl)ethylpivalate were prepared from 2-(hydroxyphenyl)ethanols using the "twisted"-amide method in toluene in 80% and 51% yield (step F) (69), respectively. These phenol derivatives were then converted into the corresponding cycloSal-phosphate triesters using the known procedures (steps G-I). As reference compounds, 3-and 5-cycloSal-acids 36,37 were prepared from t-butyl esters 40c,41c by treatment with trifluoroacetic acid in 85% yield (step K). 3-CycloSal-alcohol 38 was synthesized from the corresponding levulinyl (Lev) ester 42b. The Lev-group has been cleaved from the triester by hydrazine-hydrate treatment in 25% yield (step J) (70) . The Lev-ester of the phenol was prepared as the acetyl esters (step E). Unfortunately, the acetyl esters could not be cleaved chemically when incorporated into the cycloSal-phosphate triester structure. All triesters obtained were then studied concerning their properties to liberate the polar group by the enzymatic reaction as well as their chemical hydrolysis to yield d4TMP.
Proof of the "lock-in" Concept
First, chemical hydrolysis studies were conducted. The results are summarized in (Table 4) . As expected, all new triesters were cleaved to yield d4TMP at pH 7.3 in 25 mM phosphate buffer. Half-lives were found to be between 7.3 and 13.5 hours in the case of the 3- A comparison with the 3-(2f; t 1/2 = 17.5 h) and 5-methyl-cycloSal-d4TMP triesters (t 1/2 = 8.1 h) proved that the ethylene-spacer separates the electron-withdrawing ester group and the cycloSal-aromatic ring sufficiently. Interestingly, both free acid-cycloSald4TMP triesters 36,37 showed up to two-fold higher halflives as compared to the neutral ester-modified cycloSaltriesters. A possible explanation for this effect may be the presence of an overall negative charge on the molecule due to the formed carboxylate at pH 7.3, which slows down the nucleophilic reaction necessary for the initial cleavage step.
As expected, 3-cycloSal-triester 38 having the hydroxyl group in the side chain did not show such an increase in the half-lives (t 1/2 = 12.6 h; Table 4 ). This value is very close to the esters 42a,c and the levulinyl-ester 42b (t 1/2 = 12.5-13.6 h). In addition, the hydrolysis of 3-MePr-cycloSal-d4TMP 40a followed by 31 P-NMR showed that also the phenyl phosphate diester was formed in a minor extend (~2%). However, this amount is considerably lower as compared to the situation found for 3-methyl-cycloSal-d4TMP 2f (5.5%). In both experimental set-ups for chemical hydrolysis, no cleavage of the carboxylic ester group was observed.
Next, studies in 25 mM phosphate buffer (pH 7.3) containing 50 units of pig liver esterase (PLE) were carried out as a model for the enzymatic cleavage of the carboxylic esters (Table 2 ). It was observed that the halflives of the 3-modified cycloSal-triesters 40 (methyl-, ipropyl and t-butyl-esters) were slightly lowered as compared to the situation in pure phosphate buffer. However, no trace of the expected cycloSal-triester acid 36 could be detected. Thus, no enzymatic cleavage took place. In contrast, the acetyl and the pivaloyl triester 42a,c showed a two-fold decrease in the half-lives, and alcohol 38 was observed in the HPL-chromatograms. Interestingly, the situation was different for the 5-modified cycloSal4TMPs. Here, none of the studied esters of the cycloSald4TMP acid 37 and the cycloSal-d4TMP alcohol 39 were hydrolyzed. In conclusion, the outcome of these cleavage studies using PLE was disappointing. It should be added that first experiments using the methyl ester of the 3-propionatecycloSal-mask showed an extremely fast deesterification under the same conditions. Therefore, we also expected a fast ester hydrolysis in most of the cases of the cycloSal-triesters 40. Nevertheless, d4TMP 9 was formed in all cases as a result of a chemical hydrolysis of the phosphate triester entity.
Further studies were done in CEM/O cell extracts. Triesters were incubated for 10 hours at 37°C (Table 4 ). The acetyl-(42a) and the levulinyl ester of the cycloSal-d4TMP alcohol 42b showed the most impressive result. These triesters were degraded 6-to 7-fold faster as compared to the buffer incubations, and the intermediate alcohol 38 was clearly detected in the chromatogram. So, the cleavage capacity of the extracts was markedly higher as compared to the isolated enzyme PLE. However, the enzyme responsible for the ester hydrolysis in the extracts is not known. The pivaloyl ester 42c was also cleaved (half-life dropped two-fold) while all the other esters were again not cleaved. In the 5-ester-modified cycloSal-d4TMP series 41,43, only the acetyl ester 43a showed a two-fold decrease in stability. In conclusion, the acetyl esters were proven to be good substrates for the human esterases while all alkyl esters were not cleaved by the extracts. However, the final products of the complete chemical hydrolysis of all triesters were d4TMP and the salicyl alcohols 11 again.
The reason for the insusceptibility of the alkyl esters is surprising because alkyl esters are often used in prodrug strategies and at least the phosphoramidate approach developed by the McGuigan group is based on an initial cleavage of such an ester group (71) . However, esters of natural α-amino acids are used in their case.
It was interesting to note that in studies of the corresponding BVdUMP triesters also the benzyl esters were cleaved in P3HR-1 cell extracts in addition to the acetyl ester (data not shown). So, obviously the cleavage is also dependent on the nature of the nucleoside analog. However, we can not exclude that the extracts from P3HR-1 cells contain different esterases or different concentrations of esterases as CEM cell extracts.
Antiviral Activity
Finally, the triesters were tested for their antiviral potency in CEM/O cells infected with HIV-1 and HIV-2 as well as in HIV-2-infected CEM/ TK -cells. The results are summarized in (Table 4 ).
All cycloSal-triesters proved to be active in the wild-type cell line against both virus types. Only the 5-tBuester 41c was found to be 5-fold less active against HIV-2 as compared to the reference compound d4T. More interesting are the results obtained in the thymidine kinase deficient CEM cells (CEM/ TK -). First, both cycloSaltriesters 36 and 37 having the unesterified acid functionality in the side chain lost all their antiviral activity in the mutant cell line. The reason is the charge at the carboxylate which prevents an efficient membrane penetration. However, this result shows that in the case of a liberation of the carboxylate inside the cell by an enzymatic cleavage, the resulting polar product would stay trapped inside the cell. This is the first hint that the planned lock-in mechanism should work. Moreover, and in contrast to the parent d4T, all cycloSal-triesters bearing alkyl esters in the 5-or 3-position of the cycloSal-aromatic ring retained their antiviral activity in the CEM/ TK -cells (EC 50 1-2 µM) and thus proving at least the TK-bypass envisaged by these pronucleotides. Taking into account the results of the cell extract studies, no additional effect of the lock-in could be expected. However, cycloSal-triesters 42a and 43a that were enzymatically cleaved in the extracts showed lower EC 50 values in the CEM/ TK -cells. Although these triesters do not liberate a charged carboxylate but a more polar neutral alcohol group (38 and 39, respectively), it appears that these compounds show first evidence for a successful trapping inside the cells.
CONCLUSION
Summarizing, the cycloSal approach convincingly demonstrated the intracellular delivery of active nucleotides by a non-enzymatically induced cascade reaction. Compared to other pronucleotide systems, one advantage of cycloSal prodrugs is their easy synthesis and their reasonable solubility in aqueous media. Moreover, the drug/masking group ratio for cycloSal prodrugs is 1:1 only whereas almost all enzymatically triggered nucleotide delivery systems show a ratio of 1:2 or 1:4. The 1:1 ratio may be favorable in terms of reducing potential toxicity. As reported earlier, the cycloSal-pronucleotide system is further an ideal tool to study biochemical pathways in nucleoside metabolism. Modification of the cycloSalmoiety and particularly of the benzyl position led to considerable differences in the hydrolysis pathway. This allowed further insights into the mechanism of degradation and at the same time gave clues to improve the d4TMP delivery. It has considerably improved the antiviral activity of certain nucleoside analogs using the first generation cycloSal-triesters. First attempts have been made to influence the equilibrium formed by a lipophilic phosphate triester through the membrane resulting in the development of second generation cycloSal-triesters having an ester bearing side chain in the cycloSal-aromatic ring. So far, only acetyl-and (partly) pivaloyl-esters were found to be substrates for cellular esterases. Nevertheless, the liberation of a negatively charged carboxylate would be advantageous in order to achieve an efficient intracellular trapping ("lockin") of the triester. Work in order to achieve this goal is currently in progress in our laboratories.
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